Fosdevirine

Fosdevirine

Clinical data
Other names	GSK2248761; GSK2248761A; IDX-12899; IDX-899
ATC code	None
Identifiers
IUPAC name 5-Chloro-3-[[3-[(E)-2-cyanoethenyl]-5-methylphenyl]-methoxyphosphoryl]-1H-indole-2-carboxamide
CAS Number	1018450-26-4
PubChem CID	44232529
ChemSpider	28529638
UNII	Z4I0C281BJ
KEGG	D09906
ChEMBL	ChEMBL2104968
Chemical and physical data
Formula	C20H17ClN3O3P
Molar mass	413.80 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC(=CC(=C1)/C=C/C#N)[P@](=O)(C2=C(NC3=C2C=C(C=C3)Cl)C(=O)N)OC
InChI InChI=1S/C20H17ClN3O3P/c1-12-8-13(4-3-7-22)10-15(9-12)28(26,27-2)19-16-11-14(21)5-6-17(16)24-18(19)20(23)25/h3-6,8-11,24H,1-2H3,(H2,23,25)/b4-3+/t28-/m1/s1 Key:CGBYTKOSZYQOPV-ASSBYYIWSA-N

Fosdevirine is an experimental antiviral agent of the non-nucleoside reverse transcriptase inhibitor class that was studied for potential use in the treatment of HIV-AIDS.

It was discovered by Idenix Pharmaceuticals and was being developed by GlaxoSmithKline and ViiV Healthcare, but it has now been discontinued due to unexpected side effects.